NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

2019 ◽  
Vol 20 (8) ◽  
pp. 1148-1159 ◽  
Author(s):  
Sylvie Bonvalot ◽  
Piotr L Rutkowski ◽  
Juliette Thariat ◽  
Sébastien Carrère ◽  
Anne Ducassou ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document